RxDoctor Payments DataLook up a doctor →

Steven Hill, MD

Family Medicine · Newton, IANPI 1316976764

Payments from drug & device makers

$9,011in general payments, 2019–2025

Across 533 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$869
  • Pfizer$787
  • E.r. Squibb & Sons, L.L.C.$511
  • Lilly USA, LLC$506
  • AbbVie$451
  • plus $5K from 32 others

What the payments were for

  • Consulting fees$1502%
  • Food & beverage$8,80698%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,011 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$110,349
Medicare patients
223
Services billed
2,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin87$66,289
OzempicSemaglutide47$46,432
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$43,098
FarxigaDapagliflozin Propanediol52$40,054
EliquisApixaban55$36,050
TrulicityDulaglutide23$22,610
Breo ElliptaFluticasone/Vilanterol16$9,719
KerendiaFinerenone12$7,779
LinzessLinaclotide12$5,987
Ventolin HfaAlbuterol Sulfate28$3,176
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen52$2,733
Omeprazole237$2,588
DilantinPhenytoin Sodium Extended12$2,434
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,331
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$869$66,28987 claims
GSKTrelegy Ellipta, Breo Ellipta$396$52,81768 claims
Novo NordiskOzempic$380$46,43247 claims
AstraZenecaFarxiga$1,297$40,05452 claims
PfizerEliquis, Dilantin$787$38,48567 claims
Lilly USA, LLCTrulicity$506$22,61023 claims
BayerKerendia$193$7,77912 claims
AbbVieLinzess, Synthroid$451$6,52028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Newton

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →